Date: 2015-04-07
Type of information: Milestone
Compound:
Company: Amphivena Therapeutics (USA - CA) Janssen Biotech, a J&J company (USA - NJ)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
Disease:
Details:
- • On April 7, 2015, Amphivena Therapeutics, a developer of cancer immunotherapeutics, announced the achievement of the first and second milestones under the terms of its agreement with Janssen Biotech. Amphivena and Janssen have selected a clinical candidate against an undisclosed tumor antigen for further development in hematologic malignancies.
- The milestones triggered the release of payments to Amphivena. The financial details were not disclosed.
The agreement was facilitated by Johnson & Johnson Innovation.
- Amphivena’s clinical candidate is based on the RECRUIT-TandAb platform, licensed from Affimed GmbH. RECRUIT TandAbs are bispecific molecules, with two binding sites for each specificity, that mediate potent and efficient tumor cell lysis by selectively binding to a tumor antigen on a cancer cell and the CD3 receptor complex on a T cell. They offer pharmacokinetic advantages over smaller, monovalent bispecific constructs.
Financial terms:
Latest news:
Is general: Yes
